



GSK
GlaxoSmithKline
Vaccines

GSK invites you to a satellite symposium
on Thursday June 13 from 13:00-14:00 entitled
"Otitis media in the era of pneumococcal vaccines:
new data, evolving perspectives"

www.gsk.com

Date of creation: 01/06/2013 and 02/06/2013

GSK is committed to the prevention
of life-threatening diseases and to
the improvement of public health
across the globe.

GSK
GlaxoSmithKline
Vaccines

GlaxoSmithKline Vaccines registered as GlaxoSmithKline Biologicals S.A.,
rue de l'Institut 89, 1330 Rixensart, Belgium RPM Nivelles BE 0440.872.918
www.gsk.com

Stockholm, Sweden 12 - 16 June, 2013

7th Extraordinary International Symposium on Recent Advances in Otitis Media

7th Extraordinary
International Symposium
on Recent Advances in
Otitis Media

Stockholm, Sweden
12 - 16 June, 2013

Dear Colleagues and Friends,

It is our great pleasure to welcome you to the 7th Extraordinary International Symposium on Recent Advances in Otitis Media in Stockholm, Sweden on June 12-16, 2013.

It is our sincere hope that basic and clinical scientists in the field of otitis media research will join. In line with former symposia subjects addressed in the field of otitis media will be: epidemiology, diagnosis, screening, physiology, pathogenesis, microbiology, immunology, biochemistry, genetics and molecular biology, treatment, vaccines for prevention, complications and sequelae, and animal models.

The symposium is held at Clarion Hotel Sign which is located in the heart of Stockholm city, close to all city attractions.

Discover Stockholm a city like no other - a city built on 14 islands, where you are never far from the water. Well-preserved medieval buildings stand alongside modern architecture. Stockholm is also home of the Nobel Prize. And just outside the city, the archipelago of 24 000 islands is waiting to be explored.

We welcome you to Stockholm!

Sten Hellström
President

Malou Hultcrantz
Vice President

CONTENTS

Secretariat	3
Committees	4
Scientific Programme	6
Wednesday	6
Thursday	6
Friday	9
Saturday	14
Sunday	19
Program overview	20
Posters	22
Social Events	30
Instruction presentations	32
Exhibition / Sponsors	35
General Information	37

Surgical control of the mastoid cavity in chronic ear disease

Indications

- Mastoid obliteration
- Facial nerve obliteration
- Cranio-maxillofacial bone cavity filling


Benefits of BonAlive[®] granules

- Proven **bioactive growth inhibiting** property
- Provides long term support for the reconstructed posterior ear canal wall
- 15 years of clinical experience in mastoid and cranio-maxillofacial surgery


Patient case: BonAlive[®] granules in obliteration of an old radical mastoid cavity

Patient: 44-year-old female


Pre-op view



Location of the reconstructed posterior wall of the ear canal and obliteration cavity



Cholesteatoma clearance as of 2 months post-op



Post-operative image



Trans-NightView Surg Vlog post-Op view

Related articles

1. BonAlive granules (BAG) in mastoid obliteration surgery for chronic otitis media and in cranio-maxillofacial bone defects. (Goh S, Gossens R, Maerckx C, Nijssen WJ, Janssen JF, Ostry D) *Otolaryngol Neck Surg* 2017;156:1258-1263.
2. Mastoidectomy/Canal Obliteration with BonAlive Granules: A Pilot Study (Goh S, Ostry D) *Otolaryngol Neck Surg* 2017;156:1258-1263.
3. BonAlive granules (BAG) in facial flap obliteration of the mastoid cell case in otitis media with effusion. (Goh S, Nijssen WJ, Gossens R, Janssen JF, Ostry D) *Otolaryngol Neck Surg* 2017;156:1258-1263.



BonAlive granules (BAG) are a bioactive growth inhibiting property and are used in the surgical control of the mastoid cavity in chronic otitis media and in cranio-maxillofacial bone defects. The granules are made of a bioactive growth inhibiting property and are used in the surgical control of the mastoid cavity in chronic otitis media and in cranio-maxillofacial bone defects.

BonAlive granules (BAG) are a bioactive growth inhibiting property and are used in the surgical control of the mastoid cavity in chronic otitis media and in cranio-maxillofacial bone defects. The granules are made of a bioactive growth inhibiting property and are used in the surgical control of the mastoid cavity in chronic otitis media and in cranio-maxillofacial bone defects.

MEDI PLAST[®]

The Medioplast ENT products are the leading single use choice when you are looking for a vast range of suction tips and disposable accessories.

High quality
Safe products Easy and Fast



Symposium directors



Sten Hellström, MD, PhD
 Dept of Audiology & Neurotology
 Karolinska University Hospital/ Solna
 SE 171 76 Stockholm, Sweden
sten.hellstrom@karolinska.se



Malou Hultcrantz, MD, PhD
 Dept of Otorhinolaryngology
 Karolinska University Hospital/ Solna
 SE 171 76 Stockholm, Sweden
malou.hultcrantz@karolinska.se

Conference Organiser



All matters regarding Registration, Hotel Booking, Social Events, Abstract handling and General information are managed by Congrex Sweden AB.

Congrex Sweden AB
 Attn: Otitis 2013
 Visiting address: Franzéngatan 5
 PO Box 5619
 SE-114 86 Stockholm, Sweden
 Phone: +46 8 459 66 00
 Fax: +46 8 661 91 25

General requests:
otitismedia@congrex.com

Registration and hotels:
otitismedia.registration@congrex.com

Abstract handling:
otitismedia.abstract@congrex.com

Local Organizing Committee

Hellström, Sten
Hultcrantz, Malou

Programme Committee

Augustsson Ingrid
Bagger Sjöbäck, Dan
Duan, Maoli
Enoksson, Frida
Eriksson, Per-Olof
Gisselsson-Solén, Marie
Granath, Anna
Groth, Anita
Hellström,, Sten
Hemlin, Claes
Hermansson, Anne
Hultcrantz, Malou
Karlton, Eva
Laurent, Claude
Lohmander, Anette
Melhus, Åsa
Ryding, Marie
Rynnel, Britta
Stenfeldt, Karin
Tano, Krister
Tideholm, Bo
von Unge, Magnus
Westman, Eva

International Advisors

Argentina	Chinksi, Alberto
Australia	Coates, Harvey Cripps, Allan Morris, Peter Thornton, Ruth
Austria	Baumgartner, Wolf-Dieter
Brazil	Sih, Tania
Canada	Daniel, Sam J
Chile	Goycoolea, Marcos
China	Gong, Shusheng Yin, Shankai Kong, Weija Xie, Dinghau Li, Huawei Chi, Fanglu
Denmark	Caye-Thomasen, Per Homoe, Preben Lous, Jörgen Ovesen, Therese

Finland	Heikkinen, Terho Pitkäranta, Anne Ruohola, Aino
Germany	Dalchow, Carsten Hörmann, Karl
Hungary	Sziklai, Istvan
Ireland	Blayney, Alec
Israel	Leibovitz, Eugene Luntz, Michal Avraham, Karen
Italy	Barbara, Maurizio Martini, Alessandro
Japan	Lino, Yukiko Kawauchi, Hideyuki Kurono, Yuichi Yamanaka, Noboru
Norway	Bunne, Marie Kvaerner, Kari Möller, Per
The Netherlands	Schilder, Anne Rovers, Maroeska
Portugal	Spratley, Jorge
Slovakia	Jakubíková, Janka
South Korea	Choung, Yun-Hoon Kim, Hyong-Jong Hong, Sung Hwa Park, Keehyun
Spain	Urquiza de la Rosa, Raphael
Turkey	Kemaloglu, Yusuf Ozgirgin, O Nuri
United Kingdom	Brown, Steve Haggard, Mark
United States	Alper, Cuneyt Bakaletz, Lauren Barenkamp, Stephan J Casselbrant, Margareta Chonmaitree, Tasnee Chole, Richard A Daly, Kathy Juhn, Steven K Jung, Timothy Kershner, Joseph Li, Jian-Dong Lim, David Murphy, Timothy Paparella, Michael M Pelton, Stephen Poe, Dennis Rosenfeld, Richard Ryan, Allen Schachern, Patricia Swarts, J Douglas Trune, Dennis

Wednesday, June 12

15.00-19.00	Registration, Clarion Hotel Sign
19.00-21.00	Welcome reception, Clarion Hotel Sign

Thursday, June 13

07.30	Registration, Clarion Hotel Sign
08.30-09.00 B1 & B2	Welcome Sten Hellström, Sweden Malou Hultcrantz, Sweden
09.00-09.45 B1 & B2	Guest of Honour Jacob Sadé
09.45-10.15 B1 & B2	Historical Vignette of International Symposiums in Otitis Media - 1975-2013 David Lim, United States
10.15-11.00	Coffee / Poster group I / Exhibition
11.00-11.30 B1 & B2	WHO representative Shelley Chuddle
11.30-12.45 B1 & B2	S1 Round Table - Global Differences in Otitis Media Chair: Preben Homøe Co-chair: Tania Seth
11.30-11.35	Global differences in otitis media: Why is this interesting? Preben Homøe, University of Copenha- gen, Copenhagen, Denmark
11.35-11.55	Epidemiology and treatment of otitis media in Indian children Rupa Vedantam, Christian Medical Col- lege, Vellore, India
11.55-12.10	Epidemiology of otitis media associated hearing loss – the Greenlandic expe- rience Ramon G. Jensen, Rigshospitalet, Copen- hagen, Denmark
12.10-12.25	Understanding otitis media- can we learn anything new from Australian Aboriginal children? Peter Morris, Menzies School of Medi- cine, Darwin, Australia
12.25-12.40	Challenging OM diagnosis and its consequences in developing countries: emphasis on Latin America Tania Sih, University of Sao Paulo, Brasil
12.40-12.45	Discussion
12.45-14.00	Lunch

13.00-14.00 B1 & B2	GSK Symposium Otitis Media in the Era of Pneumococcal Conjugate Vaccines: New Data, Evolving Perspectives? Chair: Sven-Arne Silfverdal	
13.05-13.20		The burden of otitis media Colin Barber
13.20-13.35		Real life impact of pneumococcal vac- cines after a decade: lessons learned Anne Vergison
13.35-13.50		The role of PHiD-CV in prevention of oti- tis media: evidence from double-blind randomised clinical trials Xavier Sáez-Llorens
13.50-14.00		Q&A
14.00-14.25 B1 & B2	Keynote Molecular Biological Studies of Otitis Media: Immune Defense, Pathogenesis and Therapy Allen F Ryan, La Jolla, United States	
14.25-15.30 B1 & B2	S2 - Molecular Medicine and Genetics in Otitis Media Chair: Allen Ryan Co-chair: Qing Yin Zheng	
14.25-14.37		Mutation in the Phex gene predisposes BALB/c-Phex(Hyp-Duk)/Y mice to otitis media. Fengchan Han, Case Western Reserve University, Cleveland, United States
14.37-14.49		Mining the Down Syndrome mouse library identifies critical regions respon- sible for chronic otitis media Mahmood Bhutta, University of Oxford and MRC Harwell, United Kingdom
14.49-15.01		Fine mapping risk variants of chronic otitis media: Targeted resequencing approach with follow up genotyping. E. Kaitlynn Allen, University of Virginia, Charlottesville, United States
15.01-15.13		Genetic susceptibility to chronic otitis media with effusion (COME): candidate gene SNPs. Carol MacArthur, OHSU, Portland, United States
15.13-15.25		Candidate tumor suppressor Ecrg4 at- tenuates the inflammatory of mucosal epithelial cells to infection. Arwa Kurabi, University of California, San Diego, United States
15.30-16.00	Coffee / Poster group I */ Exhibition	
16.00-16.30 B1	Keynote Long-term Effect Consequences of Otitis Media on Language Acquisition Ellen Gerrit, Maastricht and Utrecht, The Netherlands	

16.30-17.00 B1	Keynote Long-term Effects of Otitis Media on Speech Perception and Language in School Aged Children Anne Zumach, Maastricht and Heerlen, The Netherlands	
17.00-18.00 B1	S3 - Speech and Language Chair: Anette Lohmander Co-chair: Traci Flynn	
17.00-17.05		Update of the Impact of OME on speech, language and communication in typical and adverse conditions Anette Lohmander, Karolinska Institutet, Stockholm, Sweden
17.05-17.20		Hearing and otitis media with effusion related to cleft palate Traci Flynn, Gothenburg/Stockholm, Sweden
17.20-17.28		ABR thresholds in children born with CLP and OME and children with OME Helena Sundman, Stockholm, Sweden
17.28-17.40		Speech-Language development in cleft palate and possible impact of OME Anette Lohmander, Stockholm, Sweden
17.40-18.00		Discussion
16.00-18.30 B2	S4 Round Table - Emergin Pathogens Chair: Åsa Melhus Co-chair: Harvey Coates	
16.00-16.30		Emerging pathogens; Resistance in Bacteria Åsa Melhus, University Hospital of Uppsala, Uppsala, Sweden
16.30-17.00		Fusobacterium necrophorum - a virulent anaerobe in the respiratory tract Elisabet Holst, Lund, Sweden
17.00-17.30		Multiresistant Pseudomonas aeruginosa - challenges and possibilities Christian Giske, Stockholm, Sweden
17.30-18.00		Staphylococci on the move Åsa Melhus, Uppsala, Sweden
18.00-18.30		Are the group A streptococci re-emerging? Åsa Melhus, Uppsala, Ann Hermansson, Lund, Sweden
		Discussion
19.00	Reception at The City Hall of Stockholm	

Friday, June 14

08.15-09.30 B1 & B2	S5 - Innate Immune Mechanisms Chair: Anna Granath Co-chair: Sung Moon	
08.15-08.20		Introduction Anna Granath, Karolinska University Hospital, Stockholm, Sweden
08.20-08.35		Upper respiratory tract virus-mediated dysregulation of innate immunity contributes to the pathogenesis of otitis media Lauren Bakaletz, The Ohio State University College of Medicine, United States
08.35-08.50		Regulation of inflammation and novel anti-inflammatory strategies Jian-Dong Li, Georgia State University, Atlanta, United States
08.50-09.05		Immune mechanisms in the middle ear Allan Cripps, Griffith University, Australia
09.05-09.20		Hypoxia signaling in the pathogenesis and therapy of chronic OM (15 min) Mahmood F Bhutta, University of Oxford and MRC Harwell, United Kingdom
09.30-10.00 B1 & B2	Keynote Regenerative Medicine in ME Perception Herman Kingma, Maastricht University, the Netherlands	
10.00-10.45	Coffee / Poster group II / Exhibition	
10.45-12.15 B1	Free Papers 1A & 1B Global Aspects, Epidemiology Family Medicine Moderators: Stephen Pelton and Roderick Venekamp	
10.45-10.57	FP1	Analysis of publications concerning otitis media 1975 - 2012 Robert Ruben, Albert Einstein College of Medicine, New York, United States
10.57-11.09	FP2	Trends in otitis media-related health care utilization in the United States, 2001-2011 Tal Marom, University of Texas Medical Branch, Galveston, United States
11.09-11.21	FP3	Which aspects of behaviour are influenced by OME, and how much? Mark Haggard, University of Cambridge, Cambridge, United Kingdom
11.21-11.33	FP4	How physical and developmental impacts of OME influence parent quality of life Snezana Andric Filipovic, Clinical Centre of Serbia, Belgrade, Serbia
11.33-11.45	FP5	Improving diagnosis of otitis media in the Australian primary health care setting - acceptability and impact of tympanometry and pneumatic otoscopy Jennifer Reath, University of Western Sydney, Sydney, Australia

11.45-11.57	FP6	National Institute for Clinical Excellence guidelines on the surgical management of Otitis Media with Effusion: are we telling parents what the options are? Laura Harrison, Nottingham University Hospitals, Nottingham, United Kingdom
11.57-12.09	FP7	Parent-reported symptoms predict acute otitis media (AOM) in infants with upper respiratory tract infection (URI) David McCormick, UTMB, Galveston, United States
12.09-12.21	FP8	Otitis media with effusion: How good is our history-taking documentation? Aman Khanna, Nottingham University Hospitals, Nottingham, United Kingdom
10.45-12.15 B2	Free Papers 2A & 2B Microbiology/Pathology Moderators: Allan Cripps and Krister Tano	
10.45-10.57	FP9	Gene copy number (GCN) variation in the beta-defensin gene cluster is associated with nasopharyngeal colonization patterns among otitis media prone children Eric A. Jones, The Research Institute at Nationwide Children's Hospital and The Ohio State University College of Medicine, Columbus, Ohio, United States
10.57-11.09	FP10	Antibodies against bacterial DNA binding protein (Integration Host Factor) enhance clearance of biofilms from Gelfoam® Kathleyn Brandstetter, Research Institute at Nationwide Children's Hospital, Columbus, United States
11.09-11.21	FP11	Mechanisms to resist antimicrobial peptides and nutritional immunity enhance persistence of nontypeable Haemophilus influenzae (NTHI) Kevin Mason, The Research Institute at Nationwide Children's and The Ohio State University, Columbus, Ohio, United States
11.21-11.33	FP12	Role of nasopharyngeal bacteria and respiratory viruses in acute symptoms of young children with and without acute otitis media Johanna Uitti, Turku University Hospital, Turku, Finland
11.33-11.45	FP13	The middle ear immune system change with age Michelle Nielsen, Rigshospitalet, Copenhagen/Gentofte, Denmark
11.45-11.57	FP14	Otitis media due to non-tuberculosis Mycobacteria's Lars Lundman, General Hospital in Karlstad, Karlstad, Sweden

11.57-12.09	FP15	Phase variation of the modA2 gene plays a role in the virulence of nontypeable Haemophilus influenzae (NTHI) in otitis media Joseph Jurcisek, The Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States
12.09-12.21	FP16	Biodegradable sustained-release antibiotic pellets: is drug release affected by mode of sterilisation and by storage? Ali Qureishi, NIHR Nottingham Biomedical Research Unit in Hearing, Derby, United Kingdom
12.15-13.30	Lunch	
13.30-15.00 B1	S6 - Middle Ear Pressure Regulation Chair: Magnus von Unge Co-chair: Michael Gaihede	
13.30-13.35		Introduction Magnus von Unge, University of Oslo, Oslo, Norway
13.35-13.45		Tympanic membrane displacement as a source of pressure buffering Joris Dirckx, Antwerp, Belgium
13.45-14.00		Anatomy and gas diffusion Bernard Ars, Brussels, Belgium
14.00-14.15		Human middle ear pressures, normal and in pathology Marianne Brattmo, Lund, Sweden
14.15-14.30		Regulation of middle ear pressure Cuneyt Alper, Pittsburg, United States
14.30-14.45		Regulation of middle ear pressure: role of neural feedback control and the mastoid Michael Gaihede. Aalborg, Denmark
14.45-15.00		Eustachian tube balloon dilatation Juha Silvola Oslo, Norway
13.30-15.00 B2	S7 - Family Medicine and Otitis Media Chair: Herbert Sandström Co-chair: David McCormick	
13.30-13.40		Introduction Herbert Sandström, Umeå, Sweden
13.40-14.00		Use of tympanometry in general practice in Denmark Jørgen Lous, University of Southern Denmark, Odense C, Denmark
14.00-14.20		Development and validation of a new grading scale for otitis media Thorbjörn Lundberg, Umeå, Sweden
14.20-14.40		Treatment of AOM in general practice in Sweden Sigvard Mölstad, Lund/Malmö, Sweden
14.40-15.00		Spontaneously draining acute otitis media in children: An observational study of clinical findings, microbiology and clinical course Thomas Neumark, Kalmar, Sweden

SCIENTIFIC PROGRAMME

15.00-15.30	Coffee / Poster group II * / Exhibition	
15.30-17.00 B1	Free Papers 3A & 3B Complications and Sequaele / Diagnosis and Screening Moderators: Alec Blayney and Weijia Kong	
15.30-15.42	FP17	Retraction as chronicity marker for developmental impact in OM(E) – no ears good, two ears bad Mark Haggard, University of Cambridge, Cambridge, United Kingdom
15.42-15.54	FP18	Assessment and management of patients with Eustachian tube dysfunction in a specialty clinic setting Cuneyt M Alper, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, United States
15.54-16.06	FP19	Audiologic and otologic implications of middle ear disease in children with a history of cleft palate Phoebe Roche, Children's University Hospital, Dublin, Ireland
16.06-16.18	FP20	Early placement of ventilation tubes in cleft lip and palate patients Tuomas Klockars, Helsinki University Central Hospital and University of Helsinki, Helsinki, Finland
16.18-16.30	FP21	Can nurses exclude acute otitis media in young symptomatic outpatients with tympanometry or acoustic reflectometry? Miia K. Laine, Turku University Hospital, Turku, Finland
16.30-16.42	FP22	Pressure chamber Eustachian tube function testing of children 3 to 7 years old with and without a history of OM Margaretha Casselbrant, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, United States
16.42-16.54	FP23	Otitis media control in children with cochlear implants – Long term prospective study Michal Luntz, Bnai Zion MC, Technion - Israel Institute of Technology, Haifa, Israel
16.54-17.06	FP24	Chronic mastoiditis in children in Sweden 1993-2007 Anita Groth, Strama, Lund, Sweden
15.30-17.00 B2	Free Papers 4A & 4B Regenerative medicine/Cell biology Moderators: Keehyun Park and Petri Olivius	

* Author present by poster

15.30-15.42	FP25	Latent progenitors or stem cells as regulators for tympanic membrane regeneration Yun-Hoon Choung, Ajou University School of Medicine, Suwon, Republic of Korea
15.42-15.54	FP26	Proteomics of cultivated human tympanic membrane keratinocytes Peder Aabel, University of Oslo, Lorenskog, Norway
15.54-16.06	FP27	Induced intracellular apoptosis in chronic Otitis media Anke Leichtle, University of Luebeck, Luebeck, Germany
16.06-16.18	FP28	Kanemaru tissue engineered myringoplasty experience in 44 patients Harvey Coates, University of Western Australia, Perth, Australia
16.18-16.30	FP29	Beyond probiotics? Krister Tano, Umeå University, Luleå, Sweden
16.30-16.42	FP30	Dissolving the glue in glue ear: Assessment of the use of Dornase alfa as an adjunct therapy to ventilation tube insertion – Preliminary safety data Ruth Thornton, University of Western Australia, Perth, Australia
16.42-16.54	FP31	Effect of Acrolein, an air pollutant in tobacco smoke, on human middle ear epithelial cells Moo Kyun Park, Soonchunhyang university College of Medicine, Bucheon, Republic of Korea
16.54-17.06	FP32	Micro-channels of the mastoid. Indications of a high mucosal vascularization by micro CT-scanning Michael Gaihede, Aalborg University Hospital, Aalborg, Denmark
17.00-18.00 B1	International Society for Otitis Media	
19.30	Symposium Dinner at Wasa Museum	

Saturday, June 15

08.15-08.45 B1 & B2	Keynote Quality of Life in Otitis Media: Practical Approaches to its Central Conceptual Importance Mark Haggard, University of Cambridge, Cambridge, United Kingdom Chair: Richard Rosenfelt	
08.45-09.45 B1 & B2	S8 Round Table - Need for Large Scaled Databasis and Multi-center Collaboration Chair: Mark Haggard Co-chair: Richard Rosenfelt	
08.45-08.53		Introduction – a biomedical scientist’s view of the scale of clinical and biological studies in ENT Joe Kerschner, Wiscosin, United States
08.53-09.05		Genetic predispositions in OM: large cohorts are needed to discover susceptibility loci Mahmood Bhutta, Oxford, United Kingdom
09.05-09.17		Fostering international collaborations in patient outcomes research for OME Laura Cassidy, Wisconsin, United States
09.17-09.29		Eurotitis-2: a 12-language standardisation databases of OM severity and profile in Europe Mark Haggard, Cambridge, United Kingdom
09.30-09.45		Discussion
09.45-10.30	Coffee / Poster group III / Exhibition	
10.30-12.00 B1	S9 Round Table - Controversies in Mastoiditis Chair: Anne Hermansson Co-chair: Kari Kværner	
10.30-10.35		Introduction and presentation
10.35-10.50		Operation or not? Why and when? Per Cayé-Thomasen, Rigshospitalet, København, Denmark
10.50-11.05		Increasing incidence of Mastoiditis after the introduction of watchful waiting? Marie Gisselsson- Solén, Dept of ENT, University Hospital, Lund, Sweden
11.05-11.20		Are the numbers and severity of complications to mastoiditis increasing? Marie Bunne, Rikshospitalet Oslo, Norway
11.20-11.35		Discussion
11.35-11.50		The same questions answered by otosurgeons from the Nordic countries
11.50-12.00		Conclusion

10.30-12.00 B2	S10 Round Table - Animal Models Chair: Jian-Dong Li Co-chair: Lena Hafrén	
10.30-11.00		Animal models of otitis media Jian-Dong Li, Georgia State University, United States
11.00-11.15		Otitis media in the Tgfr knockout mouse implicates TGF β signalling in chronic middle ear inflammatory disease Steve Brown, Medical Research Council, Harwell, United Kingdom
11.15-11.30		Replication of SNPs from the Raine cohort GWAS of otitis media in an in- dependent family population of COME/ ROM Michele M. Sale/Kaitlynn Allen, Univer- sity of Virginia, Charlottesville, United States
11.30-11.45		Association of TLR4 with childhood recurrent acute otitis media and chronic otitis media with effusion Lena Hafrén, Helsinki University Central Hospital, Helsinki, Finland
11.45-12.00		A novel model of spontaneous otitis media with effusion (OME) in the Oxgr1 knock-out mouse Joseph E Kerschner, Medical College of Wisconsin, Milwaukee, United States
12.00-13.00	Lunch	
12.30-13.00 B2	Panel of SMED	
13.00-14.30 B1	S11 - Viral and Bacterial Vaccines and Otitis Media Chair: Anne Hermansson Co-chair: Ruth Thornton	
13.00-13.05		Introduction
13.05-13.25		Viral vaccines and otitis media Tasnee Chonmaitree, University of Texas Medical Branch, United States
13.25-13.45		Pneumococcal vaccine proteins and their mechanisms of action David E. Briles, University of Alabama at Birmingham, Birmingham, United States
13.45-14.05		Surface proteins from Hi and MC as vac- cine candidates Kristian Riesbeck, Lund University, Sweden
14.05-14.25		Targeting the biofilm to identify novel vaccine candidates & developing ways to immunize non-invasively against otitis media Lauren Bakaletz, The Research Institute at Nationwide Children's Hospital, Ohio, United States
14.25-14.30		Summary

SCIENTIFIC PROGRAMME

13.00-14.30 B2	S12 Round Table - Interaction Between the Middle and Inner Ear Chair: Sten Hellström Co-chair: Jorge Spratley	
13.00-13.10		Introduction Steven Juhn, Minneapolis, United States
13.10-13.30		The round window membrane and entrance to the inner ear Marcos Goycoolea, Santiago, Chile
13.30-13.50		Interaction and hearing James Hall III, Univ of Florida, United States
13.50-14.10		Interaction and balance Margaretha Casselbrant, Pittsburgh, United States
14.10-14.30		Discussion
14.30-15.00	Coffee / Poster group III * / Exhibition	
15.00-17.00 B1	Free Papers 5A & 5B Immunology and Vaccines Moderator: Terho Heikkinen	
15.00-15.12	FP33	Identification of immunoprotective do- mains within the bacterial DNA-binding protein, Integration Host Factor Sankalp Malhotra, The Ohio State Uni- versity College of Medicine, Columbus, United States
15.12-15.24	FP34	Inhibition of Toll-like receptor signaling as a treatment for middle ear fluid and hearing impairment in Otitis media with effusion Steven Hefeneider, 13therapeutics, Inc, Portland, United States
15.24-15.36	FP35	Transcutaneous immunization with a patch resolves active experimental otitis media Kathleen Stuller, The Research Institute at Nationwide Children's Hospital, Co- lumbus, United States
15.36-15.48	FP36	Nontypeable Haemophilus influenzae and Streptococcus pneumoniae protein specific antibody responses are dif- ferent between Indigenous Australian children with otitis media, Caucasian children with otitis media and healthy non-Indigenous controls Ruth Thornton, University of Western Australia, Perth, Australia
15.48-16.00	FP37	Sublingual delivery of NTHI adhesin-tar- geted vaccine candidate as a non-inva- sive platform for immunization against experimental otitis media Lucia Rosas, The Research Institute at Nationwide Children's Hospital, Colum- bus, United States

* Author present by poster

16.00-16.12	FP38	Variation of Pneumococcal Pilus-1 expression results in vaccine failure during Experimental Otitis Media [EOM] Marisol Figueira, Boston University School of Medicine, Boston, United States
16.12-16.24	FP39	Analysis of dynamics of IL-17 in chronic middle ear inflammation induced by nontypeable Haemophilus influenzae in mice model Takashi Hirano, Oita University, Faculty of Medicine, Yufu, Japan
16.24-16.36	FP40	Impact of 13-valent pneumococcal conjugate vaccine on otitis media in young children in the United States Tal Marom, University of Texas Medical Branch, Galveston, Texas, United States
16.36-16.48	FP41	Effectiveness of the 10-valent pneumococcal conjugate vaccine against tympanostomy tube placements in a cluster-randomized trial Arto Palmu, National Institute for Health and Welfare, Tampere, Finland
16.48-17.00	FP42	Mucociliary abnormalities lead to altered expression of BPII/PLUNC proteins in murine models of otitis media Apoorva Mulay, University of Sheffield, Sheffield and Medical Research Council, Didcot, United Kingdom
15.00-17.00 B2	Free Papers 6A & 6B Medical and Surgical Treatment Moderators: Andres Sibbald and Paola Marchisio	
15.00-15.12	FP43	Should persistent middle-ear effusion be required before recommending tympanostomy tubes for recurrent acute otitis media? Richard Rosenfeld, SUNY Downstate Medical Center, Brooklyn, NY, United States
15.12-15.24	FP44	Long term follow up of otitis media with effusion in children: Comparisons between VT group and non-VT group Hye Ran Hong, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
15.24-15.36	FP45	Protocol for a randomised controlled trial of watchful waiting versus antimicrobial treatment for acute otitis media without perforation in low risk Aboriginal children Hasantha Gunasekera, The University of Sydney, Sydney, Australia
15.36-15.48	FP46	Are children with OME being managed according to NICE guidelines? Kim To, Nottingham University Hospitals, Nottingham, United Kingdom

15.48-16.00	FP47	The benefit of antibiotics for acute otitis media in children - Influence of inclusion and outcome criteria in clinical trials Marie Gisselsson Solen, University of London, London, United Kingdom
16.00-16.12	FP48	Mineralocorticoids clear middle ear inflammation Dennis Trune, Oregon Health & Science University, Portland, United States
16.12-16.24	FP49	Vitamin D supplementation reduces the risk of new episodes of acute otitis media in otitis-prone children Paola Marchisio, University of Milan, Milan, Italy
16.24-16.36	FP50	Does the chance acquisition of virulence traits by nasopharyngeal commensal bacteria result in the evolution of increasingly pathogenic strains? Garth Ehrlich, Center for Genomic Sciences, Allegheny Singer Research Institute, Pittsburgh, United States
16.36-16.48	FP51	Guinea pig model to establish the safety of middle ear pellets Emma Hoskison, Nottingham Hearing Biomedical Research Unit, Nottingham, United Kingdom
16.48-17.00	FP52	A novel surgical technique for tubal dysfunction with a tube insertion into the eustachian tube combined with a tympanostomy tube Masahiro Morita, Kyorin University School of Medicine, Mitaka City, Tokyo, Japan
18.00	Boat trip	

Sunday, June 16

08.30-09.00 B1 & B2	Keynote Probiotics and Otitis Media Anne Pitkäranta, University of Helsinki, Finland	
09.00-10.15 B1 & B2	S13 - Biofilms and Nanotechnology Chair: Åsa Melhus Co-chair: Wenzhou Hong	
09.00-09.20		Otitis media pathogens induce gel forming mucin transcript in human middle ear epithelial cultures Jospeh E. Kerschner, University of Wisconsin, United States
09.20-09.40		Targeting integration host factor with antibody induces rapid collapse of nontypeable Haemophilus influenzae biofilms in vitro M. Elisabeth Brockson, Nationwide Children's Hospital Columbus, Ohio, United States
09.40-10.00		Haemophilus responses to nutritional immunity: effects on biofilm architecture, persistence and disease severity Kevin Mason, Nationwide Children's Hospital Columbus, Ohio, United States
10.00-10.15		Finishing remarks Åsa Melhus, Uppsala University, Sweden
10.15-11.45 B1 & B2	S14 - Middle Ear Implants, CI and BAHA, and Otitis Media Chair: Marie Bunne Co-chair: Michal Luntz	
10.15-10.20		Introduction Marie Bunne, Oslo, Norway
10.20-10.35		Otitis media, biofilms and foreign bodies – what happens?
10.35-10.50		Otitis media and cochlear implants E. Karltorp, Stockholm, Sweden
10.50-11.05		Otitis media and middle ear implants/BAHA W D Baumgartner, Vienna and Stockholm, Austria-Sweden
11.05-11.20		How to avoid complications? M Luntz, Haifa, Israel
11.20-11.40		Panel: prepared questions including questions from the audience
12.00 B1 & B2	Closing remarks and adjournment.	

Wednesday, June 12

15.00 - 19.00
Registration
Clarion Hotel Sign

19.00 - 21.00
Welcome reception
Clarion Hotel Sign

Thursday, June 13

07.30 Registration

08.30 - 09.00 Welcome (B1&B2)

09.00 - 09.45 Guest of Honour
Jacob Sadé (B1&B2)

09.45-10.15 Historical Vignette of In-
ternational Symposiums in Otitis Media
- 1975-2013

10.15-11.00
Coffee/Poster group I/Exhibition

11.00-11.30 WHO Representative

11.30-12.45
S1 Round Table - Global Differences
in Otitis Media (B1&B2)

12.45 - 14.00
Lunch

13.00- 14.00
Lunchsymposium
GSK (B1&B2)

14.00-14.25
Keynote by Allen Ryan (B1&B2)

14.25-15.30
S2 - Molecular Medicine and
Genetics in Otitis Media (B1&B2)

15.30-16.00
Coffee/Poster group I*/Exhibition

16.00-16.30
Keynote by
Ellen Gerrits (B1)

16.30-17.00
Keynote by
Anne Zumach (B1)

17.00-18.00
S3 - Speech and
Language (B1)

16.00-18.00
S4 Round Table -
Emerging
Pathogens;
Resistance in
Bacteria
(B2)

19.00 - 21.00
Reception at The City Hall of
Stockholm

Friday

08.15-09.30
S5 - Innate Imm
(B1&B2)

09.30-10.00
Keynote by Herm

10.00-10.45
Coffee/Poster g

10.45 - 12.15
Free Papers 1A&1
Global Aspects,
Epidemiology
Family Medicine
(B1)

12.15 - 13.30
Lunch

13.30 - 15.00
S6 - Middle Ear
Pressure
Regulation
(B1)

15.00-15.30
Coffee/Poster g

15.30 - 17.00
Free Papers 3A&3
Complications and
Sequels / Diagnos
and Screening (B1)

17.00-18.00
International Sc
Media
(B1)

19.30 -
Dinner at the

* Author present by poster

Friday, June 14

Gene Mechanisms

an Kingma (B1&B2)

group II/Exhibition

10.45 - 12.15
Free Papers 2A&2B
Microbiology/
Pathology
(B2)13.30 - 15.00
S7 - Family
Medicine
(B2)

group II*/Exhibition

15.30 - 17.00
Free Papers 4A&4B
Regenerative medi-
cine/Cell biology
(B2)

Society for Otitis

Wasa Museum

Saturday, June 15

08.15-08.45

Keynote by Mark Haggard (B1&B2)

08.45-09.45 S8 Round Table -
Need for Large Scaled Databasis and
Multicenter Collaboration (B1&B2)

09.45-10.30

Coffee/Poster group III/Exhibition

10.30-12.00

S9 Round Table -
Controversies in
Mastoiditis
(B1)

10.30-12.00

S10 Round Table -
Animal Models
(B2)

12.00 - 13.00

Lunch

12.30 - 13.00

Panel of SMED (B2)

13.00-14.30

S11 -Viral and
Bacterial
Vaccines and Otitis
Media (B1)

13.00-14.30

S12 Round Table
- Interaction Bet-
ween Middle and
Inner Ear (B2)

14.30-15.00

Coffee/Poster group III*/Exhibition

15.00 - 17.00

Free Papers 3A&3B
Immunology and
Vaccines
(B1)

15.00 - 17.00

Free Papers 6A&6B
Medical and
Surgical Treatment
(B2)

18.00 -

Boat trip

Sunday, June 16

08.30-09.00

Keynote by Anne Pitkäranta (B1&B2)

09.00-10.15

S13 - Biofilms and Nanotechnology
(B1&B2)

10.15-11.45

S14 - Middle Ear Implants; CI, BAHA
and Otitis Media (B1&B2)

12.00 -

Closing remarks and adjournment.
Lunchbox (B1&B2)*with reservations for changes*

Poster Group I, Thursday, June 13

Epidemiology and Natural History

P1-2	Capsule and surface protein diversity amongst pediatric ear isolates following use of conjugate vaccine David Briles, University of Alabama at Birmingham, Birmingham, United States
P1-3	Normalized immunoglobulin patterns in adults with recurrent acute otitis media and low IgG2 levels during early childhood Mattias Krakau, Karolinska University Hospital, Stockholm, Sweden
P1-4	Antenatal risk factors for chronic otitis media with effusion Rebecca Walker, University of Auckland, Auckland, New Zealand

Genetics

P1-5	Mining the Down Syndrome mouse library identifies critical regions responsible for chronic otitis media Mahmood Bhutta, University of Oxford, Oxford, United Kingdom
P1-6	A novel mouse model of otitis media – edison Michael Crompton, Medical Research Council, Oxford, United Kingdom
P1-7	Clinical and genetic peculiarities of the non-syndromal sensorineural hearing loss (SNHL) in the children of tender age Elena Merkulova, Belarusian Medical Academy of Post-Graduate Education, Minsk, Belarus
P1-8	Gene polymorphisms and susceptibility to upper respiratory tract infection and acute otitis media Johanna Nokso-Koivisto, University of Texas Medical Branch, Galveston, Texas, United States
P1-9	Phenotype modulation in the Junbo model of Otitis Media by anti-TNF- α antibody therapy and genetic background Hayley E. Tyrer, Medical Research Council, Oxford, United Kingdom

Immunology and Vaccines

P1-10	A new model for NTHi middle ear infection in the Junbo mouse mutant Michael Cheeseman, Medical Research Council, Harwell, United Kingdom
P1-11	Analysis of the mucosal immune system of middle ear and nose in SOCS1 knock out mouse model with allergic rhinitis Toshiaki Kawano, Oita University Faculty of Medicine, Oita-city, Japan

P1-12	Nasopharyngeal carriage in children up to 5 years of age and influence on otitis media in pneumococcal vaccine era Matus Macaj, Children University Hospital of Comenius University, Bratislava, Slovakia
P1-13	A comparison of the virulence of streptococcus pneumoniae protein mutants in the Chinchilla Patricia Schachern, University of Minnesota, Minneapolis, United States
P1-14	High-throughput screening of kinases regulating mucosal growth in bacterial otitis media Julia Tomlin, University of California, San Diego, United States
P1-15	Dysregulated complement activation contributes to the pathogenesis of acute otitis media in mice co-infected with influenza A virus and S. pneumoniae Hua Hua Tong, The Ohio State University, Columbus, United States
P1-16	Complement activation in pediatric patients with recurrent acute otitis media Hua Hua Tong, The Ohio State University, Columbus, United States
P1-17	Comparison of tlr2, 4 and nuclear factor kappa b expression between mucosal lesions of chronic otitis in children Snezana Jesic, University of Belgrade, Belgrade, Serbia
P1-18	Ginsenoside Rg1, a glucocorticoid receptor agonist, has anti-inflammatory effects in murine otitis media Carol MacArthur, OHSU, Portland, United States

Microbiology

P1-19	Relationship between nasopharyngeal colonization of bacterial otopathogens and Staphylococcus aureus in the first six months of life Pedro E. Alvarez Fernandez, University of Texas Medical Branch, Galveston, United States
P1-20	Otitis media with effusion and biofilms: Does co-treatment with antibiotics and mucolytics improve anti-biofilm efficacy? Katie Belfield, University of Nottingham, Nottingham, United Kingdom
P1-21	Targeting integration host factor with antibody induces rapid collapse of nontypeable Haemophilus influenzae biofilms in vitro M. Elizabeth Brockson, The Research Institute at Nationwide Children's Hospital and The Ohio State University College of Medicine, Columbus, United States

P1-22	RNA-binding protein Hfq regulates biofilm formation and pathogenicity of nontypeable <i>Haemophilus influenzae</i> Wenzhou Hong, Medical College of Wisconsin, Milwaukee, United States
P1-23	Otitis media pathogens induce gel forming mucin transcript in human middle ear epithelial cultures Joseph EKerschner, Medical College of Wisconsin, Milwaukee, United States
P1-24	<i>Haemophilus</i> responses to nutritional immunity: effects on biofilm architecture, persistence and disease severity Kevin Mason, The Research Institute at Nationwide Children's and The Ohio State University, Columbus, Ohio, United States
P1-25	Nonencapsulated <i>Streptococcus pneumoniae</i> can persistently colonize the nasopharynx and may contribute to pneumococcal infection Larry S. McDaniel, University of Mississippi Medical Center, Jackson, United States
P1-26	Distribution of rhinovirus genotypes in nasopharynx among children with acute otitis media or uncomplicated respiratory tract infection Aino Ruohola, Turku University Hospital, Turku, Finland
P1-27	Usefulness of clinical efficacy rate 50% on decision making of antimicrobial selection for pediatric acute otitis media Yuasa Jun, Wakayama Medical University, Wakayama-shi, Japan
P1-28	Non-typeable <i>Haemophilus influenzae</i> (NTHi) bacteria induce Muc5b mucin and Cxcl2 pro-inflammatory cytokine expression in mouse middle ear epithelial cells Stéphanie Val, Children's National Medical Center, Center for Genetic Medicine Research, Washington, United States

Poster Group II, Friday, June 14

Pathology and Surgery

P2-1	Three-dimensional reconstruction of the facial nerve from histologic human temporal bone sections Melissa Vianna, University of Minnesota, Minneapolis, United States
P2-2	Acute mastoiditis in children. A 10-year retrospective and validated multicenter study Kristian Anthonsen, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark
P2-3	Acute mastoiditis: The role of imaging for identifying intracranial complications Michal Luntz, Bnai Zion MC, Technion - Israel Institute of Technology, Haifa, Israel
P2-4	Acute mastoiditis in the adult patient Karin Stenfeldt, Skåne University Hospital, Lund, Sweden
P2-5	Cholesteatoma in children: morphological, molecular biological and surgical aspects Snezana Jesic, University of Belgrade, Belgrade, Serbia
P2-6	Electron microscopy changes of the chorda tympani nerve in inflammatory middle ear disease Katarina Berling, Uppsala University, Västerås, Sweden
P2-7	Canal wall down mastoidectomy with tympanoplasty and reconstruction of the external ear canal - a prospective study Michal Luntz, Bnai Zion MC, Technion - Israel Institute of Technology, Haifa, Israel
P2-8	Clinical analysis of traumatic tympanic membrane perforation June Choi, Korea University Medical Center, Ansan City, Republic of Korea
P2-9	Myringoplasty is a succesful and safe treatment of tympanic membrane perforations in children younger than 14 years. Data from the Swedish Quality Register of Otorhinolaryngology Per Olof Eriksson, Uppsala University, Uppsala, Sweden
P2-10	Success-rate after fat graft myringoplasty in children and young adults. Data from the Swedish Quality Register of Otorhinolaryngology Eva Westman, Umeå University, Sundsvall, Sweden
P2-11	Effect of different types of artificial ossicles on hearing restoration Maoli Duan, Karolinska Institute, Stockholm, Sweden
P2-12	Surgical tips and results of modified overlay tympanoplasty (Lift and repositioning technique) Shi-Nae Park, The Catholic University of Korea, Collge of Medicine, Seoul, Republic of Korea

P2-13	Semi-implantable hearing device “Bonebridge” in mandibulofacialis dysostosis (Treacher-Collins / Franceschetti Syndrome) Klaus Böheim, Landesklinikum St Poelten, St. Pölten, Austria
P2-14	Cochlear implant in patients with chronic otitis media: our experience Sung Hwa Hong, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

Diagnosis and Screening

P2-15	Screening of otitis media in children with recurrent and chronic somatic pathology Svetlana Diacova, State Medical and Pharmaceutical University “Nicolae Testemitanu”, Chisinau, Republic of Moldova
P2-16	The relevance of intradermal skin testing in the diagnosis of OME David Hurst, Tufts University, Boston, Ma, United States
P2-17	An otitis media scale (OMGRADE) for remote evaluation of tympanic membrane status using video-otoscopy Thorbjörn Lundberg, Umeå University, Umeå, Sweden
P2-18	Computed tomography evaluation in children with recurrent otitis media Marise Marques, Clementino Fraga Filho University Hospital, Rio de Janeiro, Brazil
P2-19	Wideband tympanometry: A new dimension in middle ear diagnostics Leigh Martin, Interacoustics A/S, Assens, Denmark
P2-20	Hearing screening and diagnosis of hearing impairment in Slovakia Martina Masakova, Faculty of Medicine, Comenius University, Bratislava, Bratislava, Slovakia
P2-21	Hearing test in children with CLP treated at the Stockholm Craniofacial Center, Karolinska University Hospital, Sweden Birgitta Tengroth, Karolinska University Hospital, Stockholm, Sweden

Medical and Surgical Treatment

P2-22	Our experience with the treatment of secretory otitis media in childhood Mario Milkov, Medical University of Varna,, Varna, Bulgaria
P2-23	The therapeutic effect of secondary salvage treatment in SSNHL patients Yong-Soo Park, The Catholic University of Korea/ Incheon St. Mary's Hospital, Incheon, Republic of Korea
P2-24	Does the design and material of transmyringal ventilation tube matter? Johan Knutsson, Uppsala University, Västerås, Sweden
P2-25	Otorrhea in children with tympanostomy tubes: incidence and predictors Roderick P Venekamp, UMC Utrecht, Utrecht, Netherlands
P2-26	Tympanostomy tube outcomes in function of effusion's aspiration Svetlana Diacova, State Medical and Pharmaceutical University "Nicolae Testemițanu", Moldova, Chisinau, Republic of Moldova
P2-27	The effect of middle-ear effusion and tympanostomy tubes on language development during the first two years of life Anna-Rosa Cecilie Garde, Copenhagen, Denmark
P2-28	The quality of life in children with secretoty otitis media after surgical treatment Lejla Rovëanin, Institute for children disease Clinical Center Montenegro, Podgorica, Montenegro
P2-29	Clinical characteristics of acute otitis media in children under the age of 2 years Shigeki Tsuchihashi, Wakayama Medical University, Wakayama-shi, Japan
P2-30	Symptoms as predictors of treatment outcome in children with acute otitis media Paula A. Tähtinen, Turku University Hospital, Turku, Finland
P2-31	Outcomes of tympanostomy tubes for chronic or recurrent acute otitis media in children with Down syndrome Lorien Paulson, Oregon Heath Science University, Oregon, United States

Poster Group III, Saturday, June 15

Middle Ear Mechanics and Ventilation

P3-1	Intra-operative Eustachian tube function testing during Furlow palatoplasty with and without Tensor Tenopexy Cuneyt M Alper, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, United States
P3-2	CT Imaging of the Eustachian tube lumen during the Forced Response test Cuneyt M Alper, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, United States
P3-3	Videoendoscopy for assessing Eustachian tube luminal opening Cuneyt M Alper, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, United States
P3-4	The change in the Eustachian tube function in children with repaired cleft palate Cuneyt M. Alper, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, United States
P3-5	Surface area and volume of the human mastoid based on micro-CT-scanning. Parameters dependence on image resolutions. Olivier Cros, Aalborg University Hospital, Aalborg, Denmark
P3-6	Dental arch, palatal vault and tooth morphometry in children at 6 years of age with and without a history of OM J. Douglas Swarts, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, United States
P3-7	Eustachian tube dilatatory efficiency as a predictor of future otitis course Ellen Mandel, University of Pittsburgh, Pittsburgh, PA, United States
P3-8	Triggering receptor expressed on myeloid cells (TREM)-1 expression on polymorphonuclear neutrophils enhanced the bacterial clearance from the nose in synergy with TLR4 Munehito Moriyama, Oita University, Faculty of Medicine, UFU, Japan

Otitis Media in Family Medicine

P3-9	Parental role in diagnosis of otitis media in young children: Can layman parents be taught to use tympanometry reliably Nora Erkkola-Anttinen, City of Turku Welfare Division, Turku, Finland
P3-10	Questions on hearing are clinically useful in OME – but how few are sufficient? Mark Haggard, University of Cambridge, Cambridge, United Kingdom
P3-11	Factors associated with antibiotic prescribing in children with acute otitis media Jørgen Lous, University of Southern Denmark, Odense, Denmark

P3-12	Use of antibiotics during pregnancy increases the risk of acute otitis media in early childhood Tine Marie Pedersen, Copenhagen, Copenhagen, Denmark
P3-13	Awareness of otitis media with effusion amongst consumers at retail outlets for children's goods Mamun Rashid, Royal Devon and Exeter Hospital, Exeter, United Kingdom
P3-14	Complications in children caused by pneumococcal acute otitis media Lucia Satkova, Medical Faculty of Comenius University and Children's University Hospital, Bratislava, Slovakia
P3-15	Special morphological abnormalities of complicated otitis media Luidmila Semak, "Minsk City Hospital N 9", Minsk, Belarus

Regenerative Medicine

P3-16	Experimental study of osteogenesis by in situ bone tissue engineering technique for construction of ossicular prosthesis Xue Sheng Li, Navy General Hospital, Beijing, China
P3-17	Experimental study on rescontraction of tympanic membrane patch by tissue engineering method Yong Tang, Navy General Hospital, Beijing, China
P3-18	Otitis media with effusion in allergic animal model: Functional and morphological study Shi-Nae Park, The Catholic University of Korea, College of Medicine, Seoul, Republic of Korea
P3-19	Middle ear tissue response to intratympanic injection of nanoparticles Erik Hägerström, University Hospital Rigshospitalet, Copenhagen, Denmark
P3-20	Expression of bone modeling markers in acute otitis media Rasmus Lysholdt Salomonsen, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark
P3-21	HB-EGF stimulates hyperplasia of the middle ear mucosa in bacterial otitis media Julia Tomlin, University of California, San Diego, La Jolla CA, United States



Wednesday 12th June, 19:00

Welcome Reception

The welcome reception is included in the registration fee and is held at Clarion Hotel Sign.

This reception is free if you have booked it when you registered for the symposium.



Thursday 13th June, 19:00

Reception at The City Hall of Stockholm

The symposium reception will take place at The City Hall of Stockholm, the venue for the Nobel Prize banquet.

The event is held by courtesy of The City Hall of Stockholm and the County Council. A buffet will be served followed by a guided tour of the building. This reception is free if you have booked it when you registered for the symposium.



Friday 14th June, 19:30
Symposium Dinner

The Symposium dinner will take place in the Wasa Museum with the sole artefact Wasa warship.

Enjoy a piece of Swedish history at the spectacular Vasa Museum, one of Stockholm's main attractions. If you forgot to buy a ticket for this event, please contact the registration desk at venue to check if there are seats available.



Saturday 15th June, 18.00
Boat trip

After a short boat-trip we will arrive at Fjäderholmarna, the closest archipelago island of Stockholm. The Fjäderholmarna is a part of the "Nationalstadsparken", a unique National Park with urban elements. Here you can stroll around the little island and have a look in a couple of the artisans stores in the center of the small island. The dinner will be held at Fjäderholmarnas Magasin, only a few meters from the waterline, where a dinner with wine will be served

If you forgot to buy a ticket for this event, please contact the registration desk at venue to check if there are tickets available.

Instructions for oral presentation

Duration

Symposia speakers: Presenters in invited sessions have individual timings, which is indicated in the programme.

Free paper sessions: Please note that 12 minutes have been allocated for each presenter, including time for discussion.

Instructions for PowerPoint Presentation

PowerPoint projection will be made available by means of a laptop computer and a projector in the session halls. Overhead projection or slide projection is not available. All the hardware will be provided by the Meeting to ensure consistency in technical quality and allowing for quick and smooth transitions between the speakers.

These instructions are to ensure a successful and trouble free presentation. Please follow very carefully the instructions given below.

- Only the computers provided on site can be used.
- Only PowerPoint (Office 2010, or the previous versions) running on PCs is available.
- We kindly ask you to bring your presentation on a memory stick and download your presentation on the session hall laptop at ***the latest during the coffee break/lunch break pre your session.***

Instructions for poster presentation

Posters will be displayed in 3 groups. ***Presenting authors are requested to be present by their poster during the afternoon coffee break on presentation day.***

Set up of posters

Poster group I:	13 June, 07:30-10:00
Poster group II:	14 June, 08:00-10:00
Poster group III:	15 June, 08:00-09:45

Removal of posters

Poster group I:	13 June, 18:00
Poster group II:	14 June, 18:00
Poster group III:	15 June, 17:00

Poster boards

The maximum size of your poster should be 120 cm height and 90 cm width (portrait format). Your poster material should be attached on the surface by material provided by the venue staff.

Your poster board will be marked with your poster number.

Ponto – The Bone Anchored Hearing System

More speech – Less feedback That's Ponto!



Chronic otitis media is a major cause of conductive hearing loss in both paediatric and adult populations. The conventional hearing aids that are prescribed to assist these patients can sometimes prolong their ear infections, or promote recurrence.


A bone anchored hearing system allows the ear canal to remain completely open. Sounds are received by the processor, and transmitted via vibration of the skull directly to the inner ear, bypassing the conductive component. Patients receive the necessary amplification, with the added benefit of maintaining a dry ear.

Name: Peder Soerensen

Age: 69

Indication: Chronic Otitis Media

"I have always enjoyed choir singing and concerts – but never more so than with Ponto Pro Power. When the sopranos are singing, I no longer have to turn the volume down for fear that it will start whistling."



Ponto Pro Power user



Ponto Pro user

Name: Britt Vangsbaek

Age: 50

Indication: Chronic Otitis Media

"Ponto Pro is unlike anything I've ever experienced. My previous devices were pretty good, but this is like getting high quality stereo sound, like Bang & Olufsen! The sound is clearer, broader and deeper. Speech comes through more clearly too."

To learn more about Oticon Medical and the Ponto System, please visit our booth at the 7th Extraordinary International Symposium on Recent Advances in Otitis Media.

www.oticonmedical.com

oticon
MEDICAL

Following companies are represented in the exhibition

Gold Sponsor

Möllerström Medical
MED-EL Representative Scandinavia

Silver Sponsor

oticon
MEDICAL

MEDI PLAST[®]

BonAlive[®]

informa
healthcare

Cochlear Nordic

Interacoustics

Karl Storz Endoskop

Swedish Otorhinolaryngology
Quality Register

Dear Congress Delegate!

Welcome to the 7th
Extraordinary International
Symposium on Recent
Advances in Otitis Media,
in Stockholm, Sweden!

Acta Oto-Laryngologica is a proud
silver sponsor of the symposium, and
we hope that you will enjoy five days full of
inspiration here in Sweden, the home
country of **Acta Oto-Laryngologica**!

Acta Oto-Laryngologica is a truly
international journal for translational
otolaryngology and head & neck surgery
and has become a highly respected journal
in its field. The journal presents cutting-edge
papers on clinical practice, clinical research
and basic sciences and also bridges the gap
between clinical and basic research.

We would like to invite you to the Informa
Healthcare stand where we offer all
delegates **A FREE SAMPLE COPY OF
ACTA OTO-LARYNGOLOGICA**.

Sincerely,
Informa Healthcare,
Publisher of **Acta Oto-Laryngologica**

informa
healthcare

www.informahealthcare.com

Arrival at Arlanda Airport

Airport coaches leave Arlanda airport (Stockholm's international airport) every 5-10 minutes for the City Terminal in central Stockholm. The bus ride takes approximately 35 minutes and costs SEK 198 (return ticket, February 2012). Please visit www.flygbussarna.se for further information.

From Arlanda Airport there is a direct train connection to the Stockholm Central Station, the Arlanda Express Train. The journey takes about 20 minutes, cost SEK 490 (return ticket, February 2012). The train leaves every 15 minutes from Arlanda Airport, and is specially designed with extra space for luggage. Please visit www.arlandaexpress.se for further information.

Taxis are available outside the arrival hall at Arlanda airport. Prices may vary considerably, so you are advised to ask for the price before entering the taxi. Many taxi companies offer a fixed price of SEK 495 from Arlanda airport to Stockholm city centre (SEK 495 from Stockholm city centre to Arlanda airport) and the driver is obliged to give you a printed receipt on request (February 2012).

Badges

Each participant will receive a name badge upon registration. For security reasons, all participants are requested to wear their badge during all the symposium activities and social events.

Banks and Post Offices

Banks are open between 10.00 and 15.00 on weekdays.

Some banks in central Stockholm are open from 09.00 to 17.00.

Certificate of Attendance

A certificate of attendance will be given to registered participants at the meeting.

The meeting has been given **21 CME** points, accredited by UEMS, EACCME. The American Medical Association (AMA) has an agreement of mutual recognition of continuing medical education (CME) credit with the European Union of Medical Specialties (UEMS).

Climate and Dress

The weather in Stockholm at this time of the year is usually mild with temperatures approximately 18–22 degrees Celsius, showers may occur. Informal dress is recommended.

Currency

The official currency is Swedish Krona (SEK).

USD 1 = SEK 6.66, EUR 1 = SEK 8.82 (May 2013)

Disclaimer

The Organising Committee and Congrex Sweden AB accept no liability for any injuries/losses incurred by participants and/or accompanying persons, nor loss of, or damage to, any luggage and/or personal belongings.

Electricity

Electrical current in Sweden is 220 V/50 Hz. Round, European style two-pin plugs are used. Appliances designed to operate on 110/120 Volts need a voltage converter and a plug adapter.

How to reach the venue

Go by commuter train, airport express train or bus, underground/subway or bus to Stockholm Central Station. Follow signs to the main entrance, take left and follow Vasagatan around 300 metres. When you reach the Norra Bantorget square, take left and the Clarion Sign hotel is in front of you.

Language

The official language of the symposium is English. No simultaneous translation will be provided.

Local transportation

Please note that tickets must be bought before travel. Tickets for public transport can be bought from newsagents as well as from SL (Stockholms lokaltrafik) ticket offices.

See SL's travel page for more information: www.sl.se/

Meals

Coffee and lunch is included in the registration fee and will be served daily.

On-site Registration in Stockholm

On-site registration will start Wednesday, 12 June at 15.00

The registration desk and symposium secretariat is located at Clarion Hotel Sign and will then be open during the symposium hours.

Passports and Visas

Participants are advised to make their own arrangements with respect to entering Sweden. Please note that if you wish to participate in a tour outside Sweden, you may need a multiple entry visa to Sweden.

Time Zone

The time zone in Stockholm is GMT + 1 hour.

Daylight Saving Time is used during the summer.

Tourist Information

The Symposium Secretariat will be available to give you more information about Stockholm, book tour tickets, make restaurant reservations, or assist you in any other way during your stay in Stockholm. You can also contact:

Stockholm Tourist Centre

Telephone: +46 8 508 28 500

E-mail: touristinfo@stockholm.se

www.visitstockholm.com

Visiting address: Vasagatan 14

Venue and Dates

The symposium will be held in the city of Stockholm at Clarion Hotel Sign, Östra Järnväggsgatan 35 Stockholm, 13-16 June 2013. Clarion Hotel Sign is located in the heart of Stockholm city, close to all city attractions. The hotel is situated a few minutes walk from Stockholm Central Station with underground/subway, commuter trains, buses and the Arlanda Express airport express trains.

Nasonex®

mometasonfuroat



En lösning för näsan

NASONEX (mometasonfuroat), Nässpray, suspension, en nasal kortikosteroid som väger 50 mikrogram (R, F, BPG nkl 2612).

Indikationer och dosering:

- Behandlingen och dosering:
 - Barn 5-11 år: 100 µg x 1, två gånger (inklusive äldre prepubert) och barn över 12 års ålder: 200 µg x 1, vid obefrädd symptomkontroll kan dosen ökas till 200 µg x 2. Vid symptomkontroll kan en dosreducering till 100 µg x 1 påfölja.
 - Behandling av allergisk rhinit i näsan vid akuta episoder av rinorinut hos vuxna med hyperreaktiva allergisk eller infektion med vasomotoriska nässpray: 200 µg x 2.
 - Behandling av näspolyper: 200 µg x 2, vid symptomkontroll: 200 µg x 1, och prevention av recidiv av näspolyper efter kirurgisk endoskopisk sinusskirgi (FESS) kan vara från 15 år: 200 µg x 1.

Kontraindikationer:

Överksamhet med aktiva smittsamma eller mot allvarliga hjärnsjuk. En obekräftad lokal infektion i näsan eller i paranasala sinus. Patienter som nyligen genomgått nässkirgi eller trauma ska inte ta några kortikosteroider förrän läkningen har skett.

För fullständig information vid förskrivning samt information om priser och förpackningar se www.lac.se



Börs 7126, 102 07 Stockholm, Tel 08-678 185-00, www.msd.se
08-16-MSF-108228-0000, maj 2012



Hör det senaste!

Kom gärna förbi vår monter vid entrén. Vi svarar på alla frågor om våra hörselimplantat: CI, Vibrant Soundbridge och världens första benlednings-implantat där huden lämnas orörd – Bonebridge.

Möllerström Medical | MED-EL
 MED-EL Representative Scandinavia
 Haglundsgatan 211 20 malm | info@mollestrommedical.com | www.mollestrommedical.com



MAESTRO™
System för
Cochleaimplantat




EAS™
System för
Hörselimplantat



BONEBRIDGE™
System för
Benledningsimplantat



VIBRANT SOUNDBRIDGE™
System för
Mellanörimplantat



Exhibition:

1. Cochlear Nordic
2. Informat Healthcare
3. Oticon Medical
4. Swedish Otorhinolaryngology Quality Register
5. Interacoustics
6. Mediplast
7. Karl Storz Endoskop
8. Möllerström Medical